Lansoprazole Capsule, Delayed Release
Product Images NDC 0904-6662

4 FDA label images from Major Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 0904-6662). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

764ffb33 78ad 4b91 B0b1 91b6c3cd1969 00

764ffb33 78ad 4b91 B0b1 91b6c3cd1969 00
Packaging label for Lansoprazole 30 mg delayed-release capsules, USP by Major Pharmaceuticals. It indicates the product is for oral use, unit dose form with 80 capsules per container. Contains dosage instructions, storage conditions, and distribution information. The label includes a barcode and mentions it is Rx only.*
FDA Label Image

Figure1 (Figure1)

Figure1 (Figure1)
A line graph titled 'Mean Severity of Day Heartburn By Study Day For Evaluable Patients' showing severity scores (0 to 3) on the vertical axis over 60 days from treatment start on the horizontal axis. The graph compares mean heartburn severity among three groups: placebo, lansoprazole 15 mg QD, and lansoprazole 30 mg QD, with both lansoprazole groups showing a decrease compared to placebo.*
FDA Label Image

Figure2 (Figure2)

Figure2 (Figure2)
A line graph showing the mean severity of night heartburn by study day for evaluable patients over approximately 60 days. The graph compares three groups: placebo, lansoprazole 15 mg once daily, and lansoprazole 30 mg once daily, illustrating changes in heartburn severity categorized as severe, moderate, mild, or none.*
FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure diagram of lansoprazole, the active ingredient in Lansoprazole 30 mg delayed-release capsules by Major Pharmaceuticals. The diagram shows the molecular framework including sulfur, nitrogen, oxygen atoms, and the characteristic trifluoromethyl ether group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.